1. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. (June 2021) Authors: Cremer, Paul C; Abbate, Antonio; Hudock, Kristin; McWilliams, Carla; Mehta, Jinesh; Chang, Steven Y; Sheng, Calvin C; Van Tassell, Benjamin; Bonaventura, Aldo; Vecchié, Alessandra; Carey, Brenna; Wang, Qiuqing; Wolski, Katherine E; Rajendram, Prabalini; Duggal, Abhijit; Wang, Tisha S; Paolini, Jo... Journal: Lancet Issue: Volume 3:Number 6(2021) Page Start: e410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗